Скачать с ютуб Webinar: UEG & Monday Night IBD: Best of UEG Week 2022 в хорошем качестве

Webinar: UEG & Monday Night IBD: Best of UEG Week 2022

Check out this dynamic webinar from our live event, "UEG & Monday Night IBD: Best of #UEGWeek 2022" Expert speakers: Iris Dotan (Israel), Charles Murray (UK), and Miguel Regueiro (USA) Chair: Aline Charabaty (USA) Recorded on January 28, 2023 Our target audience includes gastroenterologists, GIs in training, surgeons, subspecialists such as dieticians and psychologists, nurse practitioners, physician assistants, nurses, and other healthcare team members involved in or interested in the care of patients with IBD. The goal of this webinar? Our overarching goal is to improve the familiarity of gastroenterologists and other healthcare professionals (HCPs) involved in the treatment of patients with IBD to the most current data regarding new and emerging treatments for IBD including: • proposed mechanisms of action and clinical evidence for new and emerging therapies • the latest efficacy and safety profile of each medication (both as monotherapy and in combination) • timeline for response • durability of response • suitability based on patient characteristics • patient related outcomes as clinical trial benchmarks With this newfound information, clinicians will be better equipped to integrate these new and emerging therapies into clinical practice and close key knowledge and/or practice gaps around care and management of patients with IBD. Relating to abstracts 1. Abstract OP196 - Ozanimod TRUE NORTH Extension Study 2. Abstract OP086 - Etrasimod ELEVATE UC 52 & UC 12 Trials 3. Abstract OP086 - Adalimumab Dose Internal Study 4. Abstract OP152 - Tofacitinib in UC RWE Study 5. Abstract OP001 - Upadacitinib in UC ACHIEVE Maintenance Study 6. Abstract LB11 - IL-23 Receptor Genetics Study 7. Abstract OP126 - Risankizumab SQ Maintenance Study in Crohn's 8. Abstract PO468 - Mirikizumab Fatigue & PRO Study in Crohn's 9. Abstract OP087 - VEGA Study of Guselkumab & Golimumab followed by GUL Monotherapy 10. Abstract MP244 - Matching-Adjusted Indirect Comparison of Upadacitinib vs Vedolizumab Induction in UC Study Learn more about UEG and our #myUEGcommunity at https://ueg.eu Learn more about the webinar itself at http://ueg.eu/week-mnibd Support by edu grants from AbbVie and BMS